Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Decoy Therapeutics, Inc.Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press ReleaseDecoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), today issued a correction to its press release dated September 22, 2026 announcing the Company's warrant inducement transaction. The original press release incorrectly stated that...
- Faruqi & Faruqi LLPUNCY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. -...
- Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name ChangeHelus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the voting results for each of the matters presented at the Company’s annual and special meeting of shareholders held on September 22, 2026 (the “Meeting”). There were 107 shareholders represented in person or by proxy at the Meeting holding 46,452,598 common shares, representing 63.58% of Helus’s total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below.
- Metal-Organic Framework (MOF) Market Gains Momentum as Carbon Capture and Clean-Energy Applications AccelerateAs per SNS Insider, the Global Metal-Organic Framework (MOF) Market is projected to reach USD 4.71 billion by 2035 as clean energy, gas separation, catalysis and pharmaceutical applications expand adoption of advanced porous materials
- Decoy Therapeutics, Inc./C O R R E C T I O N -- Decoy Therapeutics, Inc/In the news release, Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding, issued 22-Sep-2026 by Decoy Therapeutics, Inc over PR Newswire, we are advised by the company that the original version contained incorrect information introduced...
- UNCY Deadline Alert: SueWallSt Reminds Unicycive Therapeutics, Inc. (UNCY) Investors of Securities Class Action Deadline on November 2, 2026A securities class action alleges Unicycive Therapeutics told investors its third-party manufacturer had made "significant progress" toward regaining FDA compliance, while the Company had never verified that claim through its own inspection of the facility
- $3.88 Billion Drug Discovery Informatics Market Forecast Report, 2026-2032"Drug Discovery Informatics Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.
- Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesityPress release – No. 17 / 2026
- Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin SyndromeAshburn, Virginia, September 22nd, 2026, FinanceWire – First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy – Second Fast Track Designation Granted to QRX003, in Addition to Netherton Syndrome – Fast Track Designation Facilitates Development and Expedites Regulatory Review of Therapies Addressing Serious Conditions with Significant Unmet Medical Need – Follows July 2026 FDA Clearance of the … Continue reading "Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome"
- Endovia Health Sciences Closes Initial Funding to Accelerate CannEpil® Development Amid Growing Federal Support for Botanical Drug PathwaysEndovia financing comes as FDA and Congress increase focus on advancing and incentivizing regulated development of botanical and plant-derived medicines
- Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Beta Bionics, Inc. (NASDAQ: BBNX); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law Office is Investigating Claims on Your BehalfAardvark Therapeutics (NASDAQ: AARD); Beta Bionics (NASDAQ: BBNX); PROCEPT BioRobotics Corp. (NASDAQ: PRCT); and The Simply Good Foods Co. (NASDAQ: SMPL)
- RVO Health, LLCAIQ by Fullspan Health Gives Pharma Marketers a Way to Measure and Improve Visibility in AI SearchAIQ analysis finds Fullspan Health's content appearing in up to 81% of AI citations for key condition questions, and as much as 3.6x more often than competitors across ChatGPT, Claude and Gemini — Fullspan Health™, a unified B2B healthcare platform...